EGFR and colorectal carcinoma: Anti-EGFR and oxaliplatin based chemotherapy powerfully induce CD8+ cells mobilization within the metastatic site in wt RAS CRC patients, supporting a role for the immune response in mCRC under RAS status dependence [58].